


## Supplementary Material

# **Engineered Dll4-overexpressing osteocyte-derived exosomes enhanced bone regeneration by regulating osteogenesis and angiogenesis**


Yujie Yan<sup>1†</sup>, Pengtao Wang<sup>2†</sup>, Xi Tang<sup>3†</sup>, Yuhang Wang<sup>1</sup>, Mengting Xiao<sup>2</sup>, Zhenbao Liu<sup>4</sup>, Xiaolin Tu<sup>2\*</sup>, Xian Li<sup>1,2\*</sup>

### Table of contents


<b>Figure S1-3.....</b>	<b>2</b>
<b>Figure S4-5.....</b>	<b>3</b>
<b>Figure S6.....</b>	<b>4</b>




**Figure S1.** Soluble Dll4 levels in GFP-osteocyte or Dll4-osteocyte supernatants. ELISA analysis of soluble Dll4 in supernatants from GFP-osteocyte and Dll4-osteocyte cultures. No significant difference in Dll4 concentration was observed between the two groups. Data are presented as mean  $\pm$  SD (n = 3).




**Figure S2.** Viability of BMSCs treated with Dll4-Exo. ST2 cells were cultured with Dll4-Exo at indicated concentrations (15, 50, and 75  $\mu$ g/mL) for 1 or 3 days. CCK-8 assay revealed comparable cell viability across all groups at each time point. Data are presented as mean  $\pm$  SD (n = 3).




**Figure S3.** DAPT inhibits Dll4-Exo-induced Notch target gene expression in HUVECs. HUVECs were treated with PBS or Dll4-Exo in the presence or absence of DAPT for 3 days, followed by qRT-PCR of Notch target genes (*Hes1*, *Hey1*, *HeyL*). \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001 for Dll4-Exo without DAPT vs. PBS without DAPT; #p < 0.05, ##p < 0.01, ###p < 0.001 for Dll4-Exo without DAPT vs. Dll4-Exo with DAPT.



**Figure S4.** *In vivo* tracking of DiD-labeled exosomes. Representative fluorescence images showing the distribution of Dil-labeled exosomes (red) at 1 h after local injection into the fracture site.



**Figure S5.** Comparison of the four elevated miRNAs (miR-23a-5p, miR-335-3p, miR-741-3p and miR-692) between GFP-Exo and Dll4-Exo using qRT-PCR. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$  vs. GFP-Exo group.



**Figure S6.** miR-23a-5p mediates the osteogenic effects but not the angiogenic effects of Dll4-Exo. (A-C) qRT-PCR of (A) osteogenic marker genes (*Alpl*, *Runx2*, *Osx*), (B) Notch receptors (*Notch1*, *Notch2*), and (C) Notch signaling genes (*Hes1*, *Hey1*) in ST2 cells under six treatment conditions: PBS control, Dll4-Exo, Dll4-Exo + mimic-NC, Dll4-Exo + mimic-miR, Dll4-Exo + inhib-NC, and Dll4-Exo + inhib-miR. (D-E) Transwell migration assay of HUVECs under the same six conditions: representative images (D) and quantitative analysis (E) of migrated cells (scale bar = 400  $\mu$ m). (F-G) qRT-PCR of (F) Notch signaling genes (*Hes1*, *Hey1*) and (G) angiogenesis-related genes (*Hif1a*, *E-cad*, *Vegf*, *HeyL*) in HUVECs under the six treatment conditions.  $^{\#}p < 0.05$ ,  $^{\#\#}p < 0.01$ ,  $^{\#\#\#}p < 0.001$  vs. PBS control;  $^{\circ}p < 0.05$ ,  $^{\circ\circ}p < 0.01$ ,  $^{\circ\circ\circ}p < 0.001$  vs. Dll4-Exo group;  $^{\ast}p < 0.05$ ,  $^{\ast\ast}p < 0.01$ ,  $^{\ast\ast\ast}p < 0.001$  vs. respective negative control group (mimic-NC or inhib-NC).